Literature DB >> 22271564

Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.

Mina Komuta1, Olivier Govaere, Vincent Vandecaveye, Jun Akiba, Werner Van Steenbergen, Chris Verslype, Wim Laleman, Jacques Pirenne, Raymond Aerts, Hirohisa Yano, Frederik Nevens, Baki Topal, Tania Roskams.   

Abstract

UNLABELLED: Cholangiocellular carcinoma (CC) originates from topographically heterogeneous cholangiocytes. The cylindrical mucin-producing cholangiocytes are located in large bile ducts and the cuboidal non-mucin-producing cholangiocytes are located in ductules containing bipotential hepatic progenitor cells (HPCs). We investigated the clinicopathological and molecular features of 85 resected CCs (14 hilar CCs [so-called Klatskin tumor], 71 intrahepatic CCs [ICCs] including 20 cholangiolocellular carcinomas [CLCs], which are thought to originate from HPCs]) and compared these with the different cholangiocyte phenotypes, including HPCs. Immunohistochemistry was performed with biliary/HPC and hepatocytic markers. Gene expression profiling was performed in different tumors and compared with nonneoplastic different cholangiocyte phenotypes obtained by laser microdissection. Invasion and cell proliferation assay were assessed using different types of CC cell lines: KMC-1, KMCH-1, and KMCH-2. Among 51 ICCs, 31 (60.8%) contained only mucin-producing CC features (muc-ICCs), whereas 39.2% displayed histological diversity: focal hepatocytic differentiation and ductular areas (mixed-ICCs). Clinicopathologically, muc-ICCs and hilar CCs showed a predominantly (peri-)hilar location, smaller tumor size, and more lymphatic and perineural invasion compared with mixed-ICCs and CLCs (predominantly peripheral location, larger tumor size, and less lymphatic and perineural invasion). Immunoreactivity was similar in muc-ICCs and hilar CCs and in mixed-ICCs and CLCs. S100P and MUC1 were significantly up-regulated in hilar CCs and muc-ICCs compared with mixed-ICCs and CLCs, whereas NCAM1 and ALB tended to be up-regulated in mixed-ICCs and CLCs compared with other tumors. KMC-1 showed significantly higher invasiveness than KMCH-1 and KMCH-2.
CONCLUSION: Muc-ICCs had a clinicopathological, immunohistochemical, and molecular profile similar to that of hilar CCs (from mucin-producing cholangiocytes), whereas mixed-ICCs had a profile similar to that of CLCs (thought to be of HPC origin), possibly reflecting their respective cells of origin.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271564     DOI: 10.1002/hep.25595

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  109 in total

1.  miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Authors:  Laurent Ehrlich; Chad Hall; Julie Venter; David Dostal; Francesca Bernuzzi; Pietro Invernizzi; Fanyin Meng; Jerome P Trzeciakowski; Tianhao Zhou; Holly Standeford; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-01-11       Impact factor: 4.307

Review 2.  Pathology of intrahepatic cholangiocarcinoma.

Authors:  Sandrine Vijgen; Benoit Terris; Laura Rubbia-Brandt
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

Review 3.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

4.  A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.

Authors:  Hyungjin Rhee; Myeong-Jin Kim; Young Nyun Park; Chansik An
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

5.  Differentiation of two subtypes of intrahepatic cholangiocarcinoma: imaging approach.

Authors:  Kengo Yoshimitsu
Journal:  Eur Radiol       Date:  2019-03-26       Impact factor: 5.315

Review 6.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

Review 7.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 8.  Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia.

Authors:  Yasunori Sato; Motoko Sasaki; Kenichi Harada; Shinichi Aishima; Toshio Fukusato; Hidenori Ojima; Yae Kanai; Masayoshi Kage; Yasuni Nakanuma; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2013-04-25       Impact factor: 7.527

9.  Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.

Authors:  Ágnes Holczbauer; Valentina M Factor; Jesper B Andersen; Jens U Marquardt; David E Kleiner; Chiara Raggi; Mitsuteru Kitade; Daekwan Seo; Hirofumi Akita; Marian E Durkin; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2013-03-19       Impact factor: 22.682

10.  Expression of vascular endothelial growth factors and their receptors by hepatic progenitor cells in human liver diseases.

Authors:  Antonio Franchitto; Paolo Onori; Anastasia Renzi; Guido Carpino; Romina Mancinelli; Domenico Alvaro; Eugenio Gaudio
Journal:  Hepatobiliary Surg Nutr       Date:  2013-04       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.